Cargando…
Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma
A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide. TT-232 inhibi...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376778/ https://www.ncbi.nlm.nih.gov/pubmed/12556972 http://dx.doi.org/10.1038/sj.bjc.6600668 |
_version_ | 1782154737415618560 |
---|---|
author | Szende, B Horváth, A Bökönyi, G Kéri, G |
author_facet | Szende, B Horváth, A Bökönyi, G Kéri, G |
author_sort | Szende, B |
collection | PubMed |
description | A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide. TT-232 inhibited the growth of HT-18 melanoma xenografts, a dose of 5 mg kg(−1) being the most effective. Combination of 1 mg kg(−1) TT-232 with 30 or 60 mg kg(−1) DTIC (administered daily) resulted in a stronger inhibitory effect compared to TT-232 or DTIC as a single modality. Antimetastatic effect of TT-232 treatment combined with DTIC was studied using the B16 mouse melanoma muscle – lung metastasis model. The number of lung metastases of B16 melanoma could be decreased by the daily administration of 1 mg kg(−1) TT-232 or 60 mg kg(−1), but not of 30 mg kg(−1) DTIC. TT-232, combined with 30 or 60 mg kg(−1) DTIC decreased the lung metastasis number significantly lower than the control. Nearly 50% growth inhibition of HT-58 lymphoma was achieved by daily treatment with 1 mg kg(−1) TT-232. 5 mg kg(−1) etoposide, administered daily, resulted in a similar effect. The combination of 1 mg kg(−1) TT-232 and 5 mg kg(−1) etoposide was significantly more effective than TT-232 or etoposide as a single treatment. The very strong tumour growth inhibitory effect of 10 mg kg(−1) etoposide could even be increased by combination with TT-232. These experimental data suggest that TT-232 may be an effective new tool in the combination chemotherapy of malignant tumours like melanoma and lymphoma. |
format | Text |
id | pubmed-2376778 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23767782009-09-10 Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma Szende, B Horváth, A Bökönyi, G Kéri, G Br J Cancer Experimental Therapeutics A novel somatostatin analogue, TT-232 (which inhibits the proliferation of various cell cultures and transplantable mouse tumours), was examined regarding its effect on human melanoma and lymphoma xenografts as a single treatment or in combination with DTIC (dacarbazine) and etoposide. TT-232 inhibited the growth of HT-18 melanoma xenografts, a dose of 5 mg kg(−1) being the most effective. Combination of 1 mg kg(−1) TT-232 with 30 or 60 mg kg(−1) DTIC (administered daily) resulted in a stronger inhibitory effect compared to TT-232 or DTIC as a single modality. Antimetastatic effect of TT-232 treatment combined with DTIC was studied using the B16 mouse melanoma muscle – lung metastasis model. The number of lung metastases of B16 melanoma could be decreased by the daily administration of 1 mg kg(−1) TT-232 or 60 mg kg(−1), but not of 30 mg kg(−1) DTIC. TT-232, combined with 30 or 60 mg kg(−1) DTIC decreased the lung metastasis number significantly lower than the control. Nearly 50% growth inhibition of HT-58 lymphoma was achieved by daily treatment with 1 mg kg(−1) TT-232. 5 mg kg(−1) etoposide, administered daily, resulted in a similar effect. The combination of 1 mg kg(−1) TT-232 and 5 mg kg(−1) etoposide was significantly more effective than TT-232 or etoposide as a single treatment. The very strong tumour growth inhibitory effect of 10 mg kg(−1) etoposide could even be increased by combination with TT-232. These experimental data suggest that TT-232 may be an effective new tool in the combination chemotherapy of malignant tumours like melanoma and lymphoma. Nature Publishing Group 2003-01-13 2003-01-28 /pmc/articles/PMC2376778/ /pubmed/12556972 http://dx.doi.org/10.1038/sj.bjc.6600668 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Experimental Therapeutics Szende, B Horváth, A Bökönyi, G Kéri, G Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma |
title | Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma |
title_full | Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma |
title_fullStr | Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma |
title_full_unstemmed | Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma |
title_short | Effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of B16 melanoma |
title_sort | effect of a novel somatostatin analogue combined with cytotoxic drugs on human tumour xenografts and metastasis of b16 melanoma |
topic | Experimental Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376778/ https://www.ncbi.nlm.nih.gov/pubmed/12556972 http://dx.doi.org/10.1038/sj.bjc.6600668 |
work_keys_str_mv | AT szendeb effectofanovelsomatostatinanaloguecombinedwithcytotoxicdrugsonhumantumourxenograftsandmetastasisofb16melanoma AT horvatha effectofanovelsomatostatinanaloguecombinedwithcytotoxicdrugsonhumantumourxenograftsandmetastasisofb16melanoma AT bokonyig effectofanovelsomatostatinanaloguecombinedwithcytotoxicdrugsonhumantumourxenograftsandmetastasisofb16melanoma AT kerig effectofanovelsomatostatinanaloguecombinedwithcytotoxicdrugsonhumantumourxenograftsandmetastasisofb16melanoma |